Humanin

Humanin is a small peptide notable for being a mitochondrial-derived peptide (MDP): its sequence is encoded within a region of mitochondrial DNA rather than the nuclear genome. It was first identified in the context of research on neuronal survival and has since become a recurring subject in studies of cellular stress, aging biology, and metabolic signaling.

Interest in humanin is largely investigational. It is discussed in the scientific literature as a signaling molecule that cells may release under stress, rather than as an established therapy. Claims found in some commercial or wellness materials often extend well beyond what controlled human evidence supports.

Proposed mechanisms for humanin come largely from cell and animal models and center on cytoprotection and metabolic signaling. High-level themes include:

• Acting as a stress-response signal that may support cell survival pathways under adverse conditions
• Interacting with receptors and intracellular pathways implicated in apoptosis (programmed cell death) regulation
• Influencing metabolic and insulin-related signaling in some experimental systems

Because humanin is part of the mitochondrial-derived peptide family, it is often studied alongside peptides such as MOTS-c, which is also encoded in mitochondrial DNA but is distinct in sequence and emphasis. How these mechanistic observations translate into meaningful human outcomes remains an open research question.

Humanin is not an approved medicine for any condition. It appears in the scientific literature as a research tool and biomarker of interest, particularly in studies related to neurodegeneration models, metabolic stress, and aging.

Any discussion of humanin should be framed as exploratory. The gap between early-stage signaling research and established clinical treatment is substantial, and regulatory status, product quality, and evidence strength all vary. Local regulations and the distinction between research interest and proven therapy should guide any consideration of the peptide.

Athletes subject to anti-doping testing should treat any non-approved investigational peptide as potentially prohibited and consult their governing body or anti-doping authority before use. The absence of a specific listing is not the same as clearance, because the S0 category is intentionally broad.

Because rigorous human safety studies are lacking, the risks of using humanin outside a research setting are poorly defined. General considerations that apply to experimental peptides include uncertainty about long-term effects, variability in product purity and sourcing, and the possibility of unrecognized interactions.

High-level summaries cannot substitute for formal safety evaluation, and the investigational nature of humanin means that important safety questions remain unanswered.

As a mitochondrial-derived peptide, humanin is studied for its signaling behavior rather than as a defined pharmaceutical product with established human dosing. There is no approved or standardized regimen.

Any pharmacology described here summarizes conceptual research themes and does not constitute medical advice or a usage recommendation.

A detail that changes how the literature should be read: most of the published in-vivo work did not use humanin.

• Humanin (HN) — the native 24-amino-acid peptide, as originally identified from a functional screen of cDNA (Hashimoto et al., PNAS 2001).

• HNG (S14G-humanin) — a single-residue substitution of serine 14 for glycine, made after mapping which residues the rescue activity depended on, and substantially more potent than the native peptide (Hashimoto et al., J Neurosci 2001). When mice were dosed twice weekly in the lifespan and healthspan study most often cited for humanin, HNG is what they received (Yen et al., Aging 2020).

• The wider MDP family — humanin sits alongside MOTS-c and the SHLP peptides, all encoded by short open reading frames within the mitochondrial genome rather than in nuclear DNA (Yen et al., 2020). Shared origin does not imply shared effects; each is studied for different endpoints.

So an animal result reported for "humanin" may in fact belong to an engineered analogue, and a vial labelled humanin is not the molecule that produced it.

Research on humanin has explored cytoprotective and neuroprotective signaling in cell and animal models, associations between humanin levels and aging or metabolic markers, and its behavior within the broader mitochondrial-derived peptide family. This body of work has generated genuine scientific interest.

However, the evidence base is preclinical and observational for the most part. Findings from model systems and correlational studies do not establish clinical benefit in humans, and claims about humanin should be interpreted cautiously and weighed against the current, evolving state of the primary literature.

For deeper dives on this peptide, see:

• Humanin benefits and areas of interest
• Humanin side effects and safety context
• Humanin dosing concepts (educational)
• Humanin research and evidence overview

What does "mitochondrial-derived peptide" mean? Nearly every protein in a human cell is encoded in the nuclear genome. Humanin is not — it is translated from a short open reading frame inside mitochondrial DNA, the small circular genome carried by the mitochondria themselves (Yen et al., Aging 2020). It was found by functional screening for something that protected neurons from familial Alzheimer's disease mutations and amyloid-beta, rather than by looking for it (Hashimoto et al., PNAS 2001).

Has humanin ever been given to a person? No. No registered clinical trial administers humanin or a humanin analogue to humans. The handful of registrations that mention it are observational studies measuring humanin concentrations in blood or tissue as an outcome — in cardiac surgery patients and in acute kidney injury, for example. There is no human dose, no human safety profile, and no human efficacy result for administered humanin.

Then what do the human studies actually show? Correlations in people's own circulating levels. Humanin generally declines with age across species; children of centenarians, who are themselves more likely to reach very old age, have substantially higher circulating humanin than age-matched controls; and levels are lower in Alzheimer's disease and in the mitochondrial disorder MELAS (Yen et al., 2020). These are associations with an endogenous molecule, and they cannot distinguish humanin being protective from humanin being a marker of mitochondria that are working well.

What was the animal evidence, precisely? In the same paper, overexpressing humanin extended lifespan in C. elegans in a daf-16/FoxO-dependent manner, humanin transgenic mice showed overlapping phenotypes, and middle-aged mice treated twice weekly with the potent analogue HNG showed improved metabolic healthspan measures and reduced inflammatory markers (Yen et al., 2020). Worth noting: the injected compound was HNG, the S14G analogue, not native humanin (Hashimoto et al., J Neurosci 2001).

Would raising humanin extend a human lifespan? Unknown, and not currently testable from the published record. The centenarian-offspring finding compared 18 offspring with 19 age-matched controls — a real observation, but a small one, and an observational one. No intervention has been shown to raise humanin in people and then produce a health outcome. Treating an association in long-lived families as a demonstrated benefit of injecting the peptide skips every step in between.

How does humanin differ from MOTS-c? Both are encoded in mitochondrial DNA and both are studied as stress-responsive signals, but they are different peptides with different sequences and different research emphases — humanin's literature centres on neuronal survival and cytoprotection, MOTS-c's on exercise and metabolic regulation. Their shared origin is a fact about the genome, not evidence that they behave alike.